Differences in Uptravi maintenance doses had no impact on the risk of hospitalization among adults with PAH, a claims ...

In The Lancet Respiratory Medicine, Olivier Sitbon and colleagues1 present the results of a randomised, phase 2b clinical trial (ELEVATE-2) that compared the safety and efficacy of pulmonary arterial ...

Most participants were receiving either three (61%) or two (35%) background drugs for PAH, and 40% were receiving prostacyclin infusions. The mean time from PAH diagnosis was 8.8 years.

Most participants were receiving either three (61%) or two (35%) background drugs for PAH, and 40% were receiving prostacyclin infusions. The mean time from PAH diagnosis was 8.8 years. Patients had a ...

Future Cardiol. 2013;9(3):335-349. Research into prostacyclin analogs for the treatment of WHO Group 2 PH has been limited, likely due to the early termination of the FIRST trial. [55] This study ...

This growth is largely attributed to the successful performance of its key products, such as Tyvaso, the leading prostacyclin treatment in the US. TD Cowen has maintained a positive outlook on ...

Theoretically, the RAS may be interrupted at any of several points in the stepwise, enzyme-catalyzed synthesis of angiotensin II, and the action of the angiotensin II molecule, once synthesized ...